The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 14 August 2026, approved vimseltinib (romvimza) for adult patients suffering from tenosynovial giant cell tumour (TGCT). This new treatment is specifically for cases where the tumour impacts movement or when surgical intervention is not possible.
TGCT is a rare, non-cancerous tumour that typically forms around a single joint, most often the knee or ankle, in young and middle-aged adults. Symptoms can include pain, swelling, stiffness, and difficulty with movement.
Julian Beach, MHRA Executive Director, Healthcare Quality and Access, stated that the approval offers a new treatment option for TGCT patients with symptoms who are unsuitable for surgery. The MHRA will continue to monitor the safety and effectiveness of vimseltinib.
Vimseltinib, the active ingredient in Romvizma, is designed to slow the growth of TGCTs by blocking specific proteins. It is administered as a capsule, taken twice a week, and is subject to additional monitoring, with a caution against use in pregnancy.